ADVISORY, June 30, 2008 (PRIME NEWSWIRE) --
What: Paul Ashton, Managing Director of pSivida Corp. (PSDV), will preside over the Closing Bell. Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio When: Tuesday, July 1 at 4:00 p.m. EDT Contacts: Beverly Jedynak IR Director pSivida Corp. bjedynak@janispr.com 312.943.1123 NASDAQ MarketSite: Jolene Libretto (646) 441-5220 Jolene.Libretto@NASDAQOMX.com
Feed Information:
The Closing Bell is available from 3:50 p.m. to 4:05 p.m. on uplink IA-6 C-band/transponder 17. The downlink frequency is 4040 Vertical; Audio 6.2-6.8. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Jolene Libretto at (646) 441-5220.
Radio Feed:
An audio transmission of the Closing Bell is also available from 3:50 p.m. to 4:05 p.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can be found on Waterfront fiber 1623 as well.
Webcast:
A live Webcast of the NASDAQ Closing Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos:
To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About pSivida Corp. (PSDV):
pSivida is committed to the development of drug delivery products in the healthcare sector, initially in ophthalmology and oncology. pSivida has developed the only two FDA approved sustained release back of the eye treatments for chronic eye disease, Vitrasert(r) and Retisert(r). Both products are manufactured and sold by global ophthalmology company Bausch & Lomb.
A next generation product, Medidur(tm), is licensed for ophthalmic applications to Pfizer Inc. Alimera Sciences has also licensed Medidur(tm) for the treatment of Diabetic Macular Edema, the leading cause of vision loss for Americans under the age of 65, which is presently in fully recruited Phase III clinical trials that is following over 900 patients across the United States, Canada, Europe and India. These trials are being fully funded by our development partner, Alimera Sciences.
pSivida owns the right to develop and commercialize a new biomaterial, nanostructured porous silicon (BioSilicon(tm)) for multiple potential applications in healthcare with a core focus on drug delivery. The lead BioSilicon(tm) product is BrachySil(tm), a brachytherapy treatment in Phase II clinical trials, which is being developed for the treatment of inoperable pancreatic cancer.
pSivida's largest shareholder and strategic partner is Pfizer (PFE). QinetiQ (QQ.), the former United Kingdom Government Defence Evaluation & Research Agency (DERA) and Europe's largest research and development organization, is a top five shareholder.
pSivida is listed on NASDAQ (PSDV), Australian (PVA), and Frankfurt (PSI) stock exchanges and is a member of the NASDAQ Health Care Index (Nasdaq:IXHC) and the Merrill Lynch Nanotechnology Index.